Literature DB >> 9453464

Inhibition of frog skeletal muscle sodium channels by newly synthesized chiral derivatives of mexiletine and tocainide.

A De Luca1, F Natuzzi, G Falcone, A Duranti, G Lentini, C Franchini, V Tortorella, D C Camerino.   

Abstract

To search for potent use-dependent blockers of skeletal muscle sodium channels as potential antimyotonic agents, the actions of newly synthesized chiral analogs of mexiletine and tocainide were tested in vitro on sodium currents of single fibers of frog semitendinosus muscle by vaseline-gap voltage clamp method. The effect of each drug on the maximal peak Na+ transient (I(Na) max) was evaluated as both tonic and use-dependent block by using infrequent depolarizing stimulation and trains of pulses at 2-10 Hz frequency, respectively. The mexiletine analog 3-(2,6-dimethylphenoxy)-2-methylpropanamine (Me2), having an increased distance between the phenyl and the amino groups, was less potent than mexiletine in producing a tonic block but produced a remarkable use-dependent block. In fact, the half-maximal concentration (IC50) for tonic block of S(-)-Me2 was 108 microM vs. 54.5 microM of R(-)-mexiletine, but the IC50 was 6.2 times lowered by the 10 Hz stimulation with respect to the 2.4 fold decrease observed with mexiletine. The R(-)-mexiletine and the S(-)-Me2 were about twofold more potent than the corresponding enantiomers in producing a tonic block, but the stereoselectivity attenuated during use-dependent blockade. The more lipophilic 2-(4-chloro-2-methylphenoxy)-1-phenylethylamine (Me1), presently available as raceme, produced a potent and irreversible tonic block of the sodium currents with an IC50 of 29 microM, but had a less pronounced use-dependent inhibition, with a 1.9 fold decrease of the IC50 at 10 Hz. The R(-) isomer of 2',6'-valinoxylidide (To1), a tocainide derivative with an increased hindrance on the chiral carbon atom, was twofold (IC50 = 209 microM) and tenfold (IC50 = 27.4 microM) more potent than R(-)-tocainide in tonic and use-dependent block, respectively. Tocainide was almost devoid of stereoselectivity, whereas the eudismic ratio of To1 [(IC50 S(+)-To1/IC50 R(-)-To1] was 1.7. As for mexiletine and Me2, the stereoselectivity of To1 was the weaker the higher the frequency of stimulation. The cyclic pyrrolo-imidazolonic tocainide analog To2 produced a small tonic block at 500 microM, and 1 min stimulation at 10 Hz was needed to show up a 50% block of I(Na) max. All the compounds produced a left-shift of the steady-state inactivation curve correlated positively with the extent of use-dependent inhibition, with the exception of the cyclic To2 that acted as an open-channel blocker. The highly use-dependent blockers Me2 and To1 might be promising drugs to solve high frequency discharges of action potentials typical of myotonic muscles. Concomitantly the high potency of Me1 and the open-channel block exerted by To2 can represent important features to get selective blockers for skeletal muscle sodium channels.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9453464     DOI: 10.1007/pl00005118

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  8 in total

1.  Increased rigidity of the chiral centre of tocainide favours stereoselectivity and use-dependent block of skeletal muscle Na(+) channels enhancing the antimyotonic activity in vivo.

Authors:  S Talon; A De Luca; M De Bellis; J F Desaphy; G Lentini; A Scilimati; F Corbo; C Franchini; P Tortorella; H Jockusch; D Conte Camerino
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

2.  Inhibition of skeletal muscle sodium currents by mexiletine analogues: specific hydrophobic interactions rather than lipophilia per se account for drug therapeutic profile.

Authors:  Annamaria De Luca; Sophie Talon; Michela De Bellis; Jean-François Desaphy; Carlo Franchini; Giovanni Lentini; Alessia Catalano; Filomena Corbo; Vincenzo Tortorella; Diana Conte-Camerino
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-01-25       Impact factor: 3.000

3.  A practical and efficient route for the highly enantioselective synthesis of mexiletine analogues and novel beta-thiophenoxy and pyridyl ethers.

Authors:  Kun Huang; Margarita Ortiz-Marciales; Viatcheslav Stepanenko; Melvin De Jesús; Wildeliz Correa
Journal:  J Org Chem       Date:  2008-08-09       Impact factor: 4.354

4.  Spiroborate ester-mediated asymmetric synthesis of beta-hydroxy ethers and its conversion to highly enantiopure beta-amino ethers.

Authors:  Kun Huang; Margarita Ortiz-Marciales; Wildeliz Correa; Edgardo Pomales; Xaira Y López
Journal:  J Org Chem       Date:  2009-06-05       Impact factor: 4.354

5.  Increased hindrance on the chiral carbon atom of mexiletine enhances the block of rat skeletal muscle Na+ channels in a model of myotonia induced by ATX.

Authors:  J F Desaphy; D Conte Camerino; C Franchini; G Lentini; V Tortorella; A De Luca
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

6.  Evaluation of the pharmacological activity of the major mexiletine metabolites on skeletal muscle sodium currents.

Authors:  M De Bellis; A De Luca; F Rana; M M Cavalluzzi; A Catalano; G Lentini; C Franchini; V Tortorella; D Conte Camerino
Journal:  Br J Pharmacol       Date:  2006-08-21       Impact factor: 8.739

7.  Searching for novel anti-myotonic agents: pharmacophore requirement for use-dependent block of skeletal muscle sodium channels by N-benzylated cyclic derivatives of tocainide.

Authors:  Annamaria De Luca; Michela De Bellis; Filomena Corbo; Carlo Franchini; Marilena Muraglia; Alessia Catalano; Alessia Carocci; Diana Conte Camerino
Journal:  Neuromuscul Disord       Date:  2011-07-29       Impact factor: 4.296

8.  Combined modifications of mexiletine pharmacophores for new lead blockers of Na(v)1.4 channels.

Authors:  Michela De Bellis; Annamaria De Luca; Jean F Desaphy; Roberta Carbonara; Judith A Heiny; Ann Kennedy; Alessia Carocci; Maria M Cavalluzzi; Giovanni Lentini; Carlo Franchini; Diana Conte Camerino
Journal:  Biophys J       Date:  2013-01-22       Impact factor: 4.033

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.